The Generation Study is testing whether anti-amyloid drugs can prevent cognitive impairment in people with increased genetic risk of developing Alzheimer's disease at older ages.
API Generation Study
Principal investigator Eric Reiman, M.D.
A landmark prevention study provides an unparalleled opportunity to advance Alzheimer's disease science. Led by Eric Reiman, M.D., executive director of Banner Alzheimer's Institute and CEO of Banner Research, the Alzheimer's Prevention Initiative (API) Generation Study is currently testing experimental Alzheimer's treatments in individuals who carry two copies of the high-risk gene apolipoprotein E ε4 (APOE4). APOE4 is estimated to be implicated in more than 50 percent of all cases of late-onset Alzheimer's, the most common form of the disease. The Alzheimer's Association®, GHR Foundation and FBRI are jointly investing $10 million to leverage the study's infrastructure and participant base by adding three innovative components to the study:
- Tau PET imaging. Amyloid "plaques" and tau "tangles" are the two hallmarks of Alzheimer's disease. Researchers increasingly believe that plaques set the disease process in motion but tangles likely do more actual damage. Tau PET imaging is a cutting-edge technology that could help reveal when and where tangles start accumulating in the brain, with significant implications for Alzheimer's diagnosis, staging and intervention. Our investment will enable tau PET imaging at the start of the trial and a two-year follow-up for 125 participants each year.
- Remote genetic counseling. Individuals participating in the Generation Study will learn they are at elevated risk for Alzheimer's — potentially distressing news. Our investment will enable a subgroup of trial participants to undergo a novel method of genetic disclosure and counseling via phone and videoconferencing. Researchers will then evaluate these remote genetic counseling approaches to improve the delivery of such information. Our investment also will make possible a study of the impact APOE genetic disclosure has on objective and subjective cognitive performance.
- Expansion of API's Alzheimer's Prevention Registry. The Registry supports enrollment in prevention studies across the country. Our funding is enabling the Registry to include online cognitive testing and GeneMatch, a first-of-its kind program for identifying potential participants by conducting their APOE genotyping by mail. APOE genotyping will enable faster enrollment in the Generation Study and in future trials.
The Alzheimer's Association must raise $2 million to complete its funding commitment to the Generation Study, which will make a major contribution to Alzheimer's detection, diagnosis and treatment.
This Project Advances:
Learn more about the key outcome areas >